Additionally, sHLA-E correlates with the expression of the specific HLA-E*01:03 allele, which suggests that both HLA-E genotype and plasma sHLA-E levels are potential biomarkers for identifying CLL patients with a high risk of early disease progression and provides the first functional clues for HLA-E-mediated immune response modulation in CLL [175]. Here, HLA-E is linked to B-cell chronic lymphocytic leukemia.